• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SEIKAGAKU CORPORATION GEL-ONE; ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SEIKAGAKU CORPORATION GEL-ONE; ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Model Number 00-1111-001-00
Device Problem Patient-Device Incompatibility (2682)
Patient Problem Hypersensitivity/Allergic reaction (1907)
Event Date 10/23/2019
Event Type  Injury  
Manufacturer Narrative
This case is received by seikagaku corporation on december 3, 2019 from the fda as mw5091186 dated (b)(6) 2019.According to the result of investigation, there were no deviations or out-of-specifications found in the manufacturing process, the in-process testing, the release testing, and the environmental monitoring for lot# 0019g08g.We attempt to contact the reporter through our us partner.
 
Event Description
On (b)(6) 2019 - a patient received gel-one injection in the knee at the patient's rheumatologist.This was the third injection in 2 years.The doctor first cleaned the area with alcohol and then she sprayed a topical numbing spray (gebaurer ethyl chloride).The doctor then injected the gel-one in the knee.The doctor asked the patient several times if the patient was ok since it was harder for the medicine to be injected this time.After the full injection was administered, the patient started feeling lightheaded, seeing stars and was really faint and then the throat started feeling weird, the patient started wheezing and having a problem breathing.The pulse was very low.The doctor called 911 she administered benadryl by injection and also, a steroid by injection and nothing was helping so they ended up using the patient's epi-pen (the patient is allergic to bees).The patient was stable and then taken to a healthcare facility for observation.The patient saw an allergist.
 
Event Description
(b)(6) 2019- a patient received gel-one injection in the knee at the patient's rheumatologist.This was the third injection in 2 years.The doctor first cleaned the area with alcohol and then she sprayed a topical numbing spray (gebaurer ethyl chloride).The doctor then injected the gel-one in the knee.The doctor asked the patient several times if the patient was ok since it was harder for the medicine to be injected this time.After the full injection was administered, the patient started feeling lightheaded, seeing stars and was really faint and then the throat started feeling weird, the patient started wheezing and having a problem breathing.The pulse was very low.The doctor called 911 she administered benadryl by injection and also, a steroid by injection and nothing was helping so they ended up using the patient's epi-pen (the patient is allergic to bees).The patient was stable and then taken to a healthcare facility for observation.The patient saw an allergist.
 
Manufacturer Narrative
This is a definitive report.H10 was updated.According to our us partner on january 14, 2020, no additional information was available in contact attempts on december 16, january 3 and 9 to the reporter.This case is received by seikagaku corporation on december 3, 2019 from the fda as mw5091186 dated november 26, 2019.According to the result of investigation, there were no deviations or out-of-specifications found in the manufacturing process, the in-process testing, the release testing, and the environmental monitoring for lot# 0019g08g.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GEL-ONE
Type of Device
ACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
SEIKAGAKU CORPORATION
marunouchi center building
6-1, marunouchi 1-chome
chiyoda-ku, tokyo 100-0 005
JA  100-0005
MDR Report Key9503583
MDR Text Key188806205
Report Number9612392-2019-00020
Device Sequence Number1
Product Code MOZ
UDI-Device Identifier00087541300912
UDI-Public(01)00087541300912(17)200825(10)0019G08G(422)392
Combination Product (y/n)N
PMA/PMN Number
P080020
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer
Type of Report Initial,Followup
Report Date 12/03/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date08/25/2020
Device Model Number00-1111-001-00
Device Catalogue Number00-1111-001-00
Device Lot Number0019G08G
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 12/03/2019
Initial Date FDA Received12/20/2019
Supplement Dates Manufacturer Received01/14/2020
Supplement Dates FDA Received01/28/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ELAVIL; ELAVIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; IMEVEXXY; IMEVEXXY; IRON; IRON; LIPITOR; LIPITOR; LOSARTAN; LOSARTAN; NEXIUM; NEXIUM; PLAQUENIL; PLAQUENIL; VIT D; VIT D; VITAMIN B12; VITAMIN B12; XYZAL; XYZAL
Patient Outcome(s) Life Threatening;
-
-